HeartSciences Inc
HSCS
$2.93 -3.93%
Exchange: NASDAQ | Sector: Healthcare | Industry: Medical Devices
Q1 2025
Published: Sep 12, 2024

Earnings Highlights

  • EPS of $-2.64 increased by 80.1% from previous year
  • Net income of -2.05M
  • "" -

HeartSciences Inc (HSCS) QQ1 2025 Results Analysis โ€” Early-Stage AI-ECG Platform Investment Drives R&D Burn with No Near-Term Revenue

Executive Summary

HeartSciences Inc (HSCS) reported QQ1 2025 results in a pre-revenue, research-intensive phase focused on AI-enhanced electrocardiography (AI-ECG) capabilities and the MyoVista device ecosystem. The quarter shows a pronounced operating burn driven by early-stage R&D and go-to-market preparation, with no revenue disclosed for Q1 2025. Key takeaways: (1) EBITDA and net income remained deeply negative as R&D and SG&A investments outweighed any cost-to-revenue contributions; (2) liquidity remains adequate on a relative basis, supported by a cash balance of approximately $4.34 million and favorable current/quick ratios, but the company carries a substantial accumulated deficit (retained earnings of about -$69.41 million) and a modest debt burden; (3) the path to value creation hinges on regulatory clearance, clinical validation, and commercial traction for the AI-ECG platform and MyoVista Insights cloud offering. Management commentary (where available) would typically address commercialization milestones, partnerships, and payer adoption; however, no earnings call transcript was provided in the data for direct quotes. Investors should regard HSCS as a high-risk, high-plex speculative opportunity tied to IP-driven growth and eventual monetization of the AI-ECG platform.

Key Performance Indicators

Operating Income

-2.08M
QoQ: -10.42% | YoY:-55.99%

Net Income

-2.05M
QoQ: -11.13% | YoY:-50.10%

EPS

-2.64
QoQ: 3.30% | YoY:80.05%

Revenue Trend

Margin Analysis

Key Insights

Revenue: Not disclosed for QQ1 2025 (revenue: null). Gross Profit: -$33,318; Gross Margin: not applicable (revenue not reported). Operating Income: -$2,075,667; EBITDA: -$1,995,849. Net Income: -$2,051,689; EPS: -$2.64. R&D Expenses: $1,224,931; SG&A/Selling, General & Administrative: $850,736. Total Operating Expenses: $2,042,349; Cost of Revenue: $33,318. Depreciation & Amortization: $33,318. Interest Expense: $22,526. Free Cash Flow: -$2,019,553; Operating Cash Flow: -$2,018,7...

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 1.90 -1.58 +0.0% View
Q3 2025 0.00 -2,572.16 +0.0% View
Q2 2025 0.00 -2.27 +0.0% View
Q1 2025 0.00 -2.64 +0.0% View
Q4 2024 0.00 -2.73 +0.0% View